OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $233,619 | -10.8% | 74,401 | +46.6% | 0.00% | – |
| Q2 2023 | $261,942 | +236.9% | 50,764 | +244.0% | 0.00% | – |
| Q1 2023 | $77,759 | +112.0% | 14,755 | +13.0% | 0.00% | – |
| Q4 2022 | $36,685 | -74.7% | 13,055 | -62.6% | 0.00% | – |
| Q3 2022 | $145,000 | +16.9% | 34,873 | +13.1% | 0.00% | – |
| Q2 2022 | $124,000 | +15.9% | 30,828 | +42.8% | 0.00% | – |
| Q1 2022 | $107,000 | -77.2% | 21,584 | -75.4% | 0.00% | -100.0% |
| Q4 2021 | $470,000 | +98.3% | 87,602 | +269.2% | 0.00% | – |
| Q3 2021 | $237,000 | -34.7% | 23,729 | -7.3% | 0.00% | -100.0% |
| Q2 2021 | $363,000 | -15.0% | 25,593 | -1.6% | 0.00% | 0.0% |
| Q1 2021 | $427,000 | -17.1% | 25,999 | +4.5% | 0.00% | 0.0% |
| Q4 2020 | $515,000 | +221.9% | 24,890 | +18.4% | 0.00% | – |
| Q3 2020 | $160,000 | -61.3% | 21,014 | -57.6% | 0.00% | -100.0% |
| Q2 2020 | $413,000 | +436.4% | 49,619 | +220.6% | 0.00% | – |
| Q1 2020 | $77,000 | – | 15,476 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,944,761 | $23,898,000 | 100.00% |
| Opaleye Management Inc. | 5,974,800 | $24,019,000 | 10.83% |
| DELTEC ASSET MANAGEMENT LLC | 2,069,313 | $8,319,000 | 1.95% |
| Kamunting Street Capital Management, L.P. | 275,506 | $1,108,000 | 1.50% |
| Altium Capital Management LP | 695,000 | $2,794,000 | 1.12% |
| Endurant Capital Management LP | 760,228 | $3,056,000 | 1.07% |
| EMERALD ADVISERS, LLC | 1,465,702 | $5,892,000 | 0.30% |
| MSD Partners, L.P. | 1,016,302 | $4,086,000 | 0.25% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,044,732 | $4,200,000 | 0.24% |
| NOTTINGHAM ADVISORS, INC. | 194,266 | $781,000 | 0.11% |